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Purpose: With the emergence of various novel therapies including new generation taxane and
androgen-targeted therapies, the optimal sequence of systemic treatment in metastatic castration-
resistant prostate cancer (mCRPC) patients remains to be deﬁned. Our aim is to investigate the impact
of duration of docetaxel-based chemotherapy and postdocetaxel treatment in mCRPC patients.
Methods: The medical data of 57 Chinese mCRPC patients who received docetaxel-based chemotherapy
in two oncology centers between 2003 and 2012 were reviewed. The treatment efﬁcacy and toxicity
were determined. The potential determinants of efﬁcacy were also determined.
Results: Fifty-seven patients (median age 66 years, range 51e82 years) were given docetaxel-based
chemotherapy, of whom 48 (84.2%) received 3-weekly docetaxel (52.5e75 mg/m2) and nine (15.8%)
received weekly docetaxel (35 mg/m2). Postdocetaxel treatments were received by 31 (57.4%) patients,
including abiraterone in 13 patients and cabazitaxel in one patient. The median follow-up time was 14.3
months. The median overall survival (OS) and progression-free survival were 20.8 months and 5.8
months, respectively. In multivariate analysis, eight cycles or more of chemotherapy [hazard ratio
(HR) ¼ 0.151, P < 0.0358], use of postdocetaxel treatment (HR ¼ 0.346, P ¼ 0.0005), and hemoglobin level
of <10 (HR ¼ 5.224, P < 0.0001) were independent determinants of OS. Patients who had received
abiraterone and cabazitaxel as postdocetaxel treatment had signiﬁcantly longer OS compared with those
who received other postdocetaxel treatments (including rechallenge of docetaxel) and those who did not
receive any postdocetaxel treatment (35.3 months vs. 20.8 months vs. 15.3 months, P ¼ 0.00057).
Conclusions: The results suggest that maximizing exposure to docetaxel-based chemotherapy followed
by novel therapies would have a favorable survival impact on mCRPC patients.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Based on the results of two landmark studies, Southwest
Oncology Group (SWOG) 9916 and TAX-327, docetaxel-based
chemotherapy is currently widely administered for patients with
metastatic castration-resistant prostate cancer (mCRPC) world-
wide.1,2 Previous studies have shown that the treatment outcome
would be improved bymaximizing the exposure of mCRPC patients
to docetaxel-based chemotherapy, as long as the tolerance and
biochemical response are favorable. The optimal number of cycles of
docetaxel-based chemotherapy, however, has not been deﬁned.3,4cology, Prince of Wales Hos-
. Poon).
ier B.V. on behalf of Prostate InteThe more recent emergence of novel therapeutic agents
including abiraterone, cabazitaxel, and enzalutamide, has opened
up new research questions.5e8 Studies are ongoing to determine
the optimal sequence of these novel agents for use in the post-
docetaxel setting, and in the chemotherapy-naïve setting.9
While results of these studies are awaited, retrospective data
may provide hints to these issues. In the present study, we inves-
tigated the relation of the number of cycles of docetaxel chemo-
therapy and postdocetaxel therapies to the survival of mCRPC
patients.
2. Methods
In this retrospective study, it was noted that 57 consecutive
Chinese mCRPC patients had received docetaxel-based chemo-
therapy at two oncology centers in Hong Kong between April 2003rnational. This is an open access article under the CC BY-NC-ND license (http://
D.M.C. Poon et al. / Prostate International 3 (2015) 51e5552and December 2012. All study participants had histologically
proven adenocarcinoma of the prostate with metastatic disease
that had progressed despite the castration level of testosterone that
was achieved after anymode of castration. The deﬁnition of clinical,
biochemical, or radiological progressive disease was based on the
Prostate Cancer Clinical Trials Working Group (PCWG-2) criteria.10
The study was approved by the Institutional Review Board of the
Chinese University of Hong Kong (CRE-2012.395-T) and conducted
in accordance with the Helsinki Declaration of 1975.
Docetaxel was given either as a weekly (35 mg/m2 on Day 1, Day
8, Day 15, Day 22, and Day 29 of a 6-week cycle) or a 3-weekly
(52.5e75 mg/m2) regimen, with 5 mg prednisone twice per day.
The choice of treatment schedule was left to the discretion of the
attending oncologists. Treatment with docetaxel was continued
until disease progression, unacceptable toxicities, or patient's
refusal to continue. Granulocyte colony stimulating factor pro-
phylaxis was administered to patients at the discretion of the
attending oncologist. The prostate-speciﬁc antigen (PSA) response
was deﬁned according to the PCWG-2 criteria. Patients who
showed reduction or withdrawal of the World Health Organization
(WHO) Class II or III analgesics according to the WHO analgesics
ladder during or after the chemotherapy were regarded as having
improvement in pain control. Postdocetaxel treatments were given
at progression after docetaxel. The choice of postdocetaxel treat-
ment is determined by several factors including the patient's clin-
ical condition, physician's preference, and patient affordability
(abiraterone and cabazitaxel being self-ﬁnanced items). Abirater-
one and cabazitaxel only became available to our institutions since
April 2010.8
Statistical analysis was performed using SPSS (Windows version
17.0.1.80; SPSS Inc., Chicago, IL, USA).The updated database as of
July 1, 2013 was used for the analysis. KaplaneMeier plots of
progression-free survival and overall survival (OS) were obtained
for subsets of patients segregated by each of the variables (potential
prognosticators) listed in Table 1. The log rank test was used to
assess the difference in outcome between subsets. The variables
were also subject to multivariate analyses using the Cox propor-
tional hazards regression model. A P value 0.05 was consideredTable 1
Univariate and multivariate analyses of overall survival.
Predictors Overall survival
Univariate analysi
HR (95% CI)
Age (y) 1.337 (0.454e3.93
PSA response 0.272 (0.081e0.91
Performance status 1.980 (0.852e4.60
Gleason score 1.856 (0.805e4.27
Prechemotherapy PSA 1.184 (0.539e2.60
PSADT 2.341 (0.929e5.90
Docetaxel schedule 2.016 (0.472e8.60
Symptomatic disease (yes vs. nil) 1.697 (0.575e5.00
ALP 3.752 (1.596e8.82
Severe anemia 6.472 (2.779e15.0
Visceral metastasis (yes vs. nil) 1.299 (0.427e3.95
Cycles of chemotherapy (8 cycles) 0.365 (0.135e0.98
Postdocetaxel treatment (yes vs. nil) 0.098 (0.03e0.316
Time to biochemical failure after chemotherapy <3 mo 0.238 (0.056e1.01
Time to castration failure >1 y 0.366 (0.156e0.86
Time to chemotherapy from castration failure <6 mo 1.386 (0.508e3.77
Palliative radiotherapy (yes vs. nil) 1.131 (0.764e1.28
Age, <70 years versus 70 years; PSA response, <90% versus 90% PSA decline from th
prechemotherapy PSA, <200 versus 200; PSADT, <3 months versus >3 months; Doceta
<10; cycles of chemotherapy, 8 versus <8; Time to biochemical failure after chemothe
chemotherapy from castration failure, <6 months versus 6 months.
ALP, alkaline phosphatase; CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology
PSA doubling time.signiﬁcant. The hazard ratio (HR) and the corresponding 95% con-
ﬁdence interval (CI) were calculated.
3. Results
3.1. Characteristics of patients and treatments
Table 2 summarizes the characteristics of the patient cohort. The
median follow-up durationwas 14.3 (range, 4.3e42.6) months. The
median age at the commencement of treatment was 66 (range,
51e82) years. The median prechemotherapy PSA is 168 (range,
6e2189). Thirty-four patients (59.6%) required WHO Class II or III
analgesics at the time of commencement of chemotherapy. Forty-
eight (84.2%) and nine (15.8%) patients received docetaxel as a 3-
weekly and a weekly regimen, respectively. Ten patients required
dose modiﬁcations: nine owing to hematological toxicity and one
owing to both hematological and neurological toxicities. Primary
and secondary granulocyte colony stimulating factor prophylaxis
was administered to three patients (5.3%) and one patient (1.8%),
respectively. Themedian number of cycles of chemotherapywas six
(range, 1e12), with 19 (33.3%) patients receiving eight or more
cycles of chemotherapy. The reasons for discontinuation of
chemotherapy are summarized in Table 3. Early discontinuation of
chemotherapy owing to progressive disease and poor tolerance
occurred in seven and nine patients, respectively, and they are
regarded as nonresponders in our study (28%). The other
responding patients (responders) received a median of six cycles of
chemotherapy.
3.2. Clinical efﬁcacy
Disease progression occurred in 54 patients (94.7%), seven
during chemotherapy and 47 after discontinuation of chemo-
therapy. Postdocetaxel therapies were administered to 31 patients
(57.4%), including abiraterone in 13 patients and cabazitaxel in one
patient (Table 3). Themedian OS and progression-free survival time
of the cohort were 20.8 months and 5.8 months, respectively
(Fig. 1). The 1-year OS rate was 77.8%. As a whole group,s Multivariate analysis
P HR (95% CI) P
7) 0.5972 NA
5) 0.0243 0.106 (0.016e0.713) 0.1381
4) 0.1059 NA
9) 0.1408 NA
5) 0.6738 NA
1) 0.0635 NA
7) 0.3338 NA
5) 0.3325 NA
2) 0.0012 2.000 (0.496e8.070) 0.2105
71) 0.0001 5.224 (2.119e12.881) <0.0001
6) 0.6443 NA
6) 0.0385 0.151 (0.044e0.517) 0.0358
) <0.0001 0.346 (0.124e0.967) 0.0005
7) 0.0356 0.591 (0.232e1.507) 0.2529
2) 0.0167 0.393 (0.147e1.054) 0.393
6) 0.5224 NA
1) 0.7323 NA
e baseline; performance status, ECOG 0e1 versus 2; Gleason score, <8 versus 8;
xel schedule, q1wk versus q3wks; ALP level >200; severe anemia, hemoglobin level
rapy, <3 versus 3 months; Time to castration failure, >1 versus 1 year; Time to
Group; HR, hazard ratio; NA, nonapplicable; PSA, prostrate-speciﬁc antigen; PSADT,
Fig. 1. Progression-free survival and overall survival.
Table 2
Patient demographics and treatment details.
No. (%)
Performance status (ECOG)
0 32 (56.1)
1e2 25 (43.9)
Gleason score
8 32 (56.1)
7 18 (31.6)
Unknown 7 (12.3)
Involved organs
Bone 53 (93)
Lymph node 28 (49.1)
Liver 3 (5.3)
Lung 7 (12.3)
Dose and schedule of docetaxel
3-weekly 48 (84.2)
52.5 mg/m2 1 (1.8)
60 mg/m2 8 (14)
67.5 mg/m2 3 (5.3)
75 mg/m2 36 (63.2)
Weekly (35 mg/m2) 9 (15.8)
Dose modiﬁcation
Total 10 (17.5)
Due to hematological toxicities 10
Due to neurological toxicities 1
ECOG, Eastern Cooperative Oncology Group.
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months vs. 27.2 months, P ¼ 0.028).
Overall,50% PSA decline from the baseline value was observed
in 33 (57.9%) of 57 patients. Of these patients, 16 (28.1%) showed a
PSA decline of 90% from the baseline. Improvement in pain
control was observed in 22 (64.7%) of 34 patients. Palliative
radiotherapy to painful bony metastasis and bisphosphonates
was received by 11 patients (11/22, 50%) within 3 months of
chemotherapy.
3.3. Adverse events
Hematological toxicities were the most common Grade 3e4
toxicities in this cohort (Table 3). Febrile neutropenia occurred inTable 3
Treatment-related toxicities and posttreatment status.
Grade 3 or 4 treatment-related toxicity
Grade 3 Grade 4
Anemia 5 (8.8) 1 (1.8)
Leukopenia 1 (1.8) 5 (8.8)
Neutropenia 6 (10.5) 15 (26.3)
Febrile neutropenia 7 (12.3) 1 (1.8)
Stomatitis 1 (1.8) 0
Diarrhea 1 (1.8) 0
Peripheral edema 1 (1.8) 0
Chemotherapy suspension reason
Progressive disease 7 (12.3)
Treatment-related toxicities 9 (15.8)
Chemotherapy break 18 (26.3)
Financial constraint 4 (7)
Maximum disease response achieved 19 (33.3)
Postchemotherapy treatment
None 23 (43.6)
Yes 31 (57.4)
Abiraterone 13
Cabazitaxel 1
Doectaxel rechallenge 2
Estramustine 3
Mitoxantrone 4
Antiandrogen 6
Prednisolone 5
Ketoconazole 2
Data are presented as n or n (%).eight patients (14.0%). Other Grade 3 toxicities were stomatitis,
diarrhea, and peripheral edema. None of the patients in this cohort
died from treatment-related toxicities, but treatments were dis-
continued in nine (15.8%) patients because of treatment-related
toxicities. No statistically signiﬁcant clinical factors (including age,
extent of bone metastases, or chemotherapy schedule) were asso-
ciated with febrile neutropenia.3.4. Univariate and multivariate analyses
Univariate analysis revealed six signiﬁcant predictors of OS
(Table 1). Signiﬁcant anemia (hemoglobin level < 10) (HR ¼ 5.224;
95% CI, 2.119e12.881; P < 0.0001), eight or more cycles of chemo-
therapy (HR ¼ 0.151; 95% CI, 0.044e0.517; P ¼ 0.0358), and use of
postdocetaxel treatment (HR ¼ 0.346; 95% CI, 0.124e0.967;
P ¼ 0.0005) are signiﬁcantly associated with OS in the multivariate
analysis (Table 1). Notably, signiﬁcant differences in median OS
were observed in patients who received abiraterone and cab-
azitaxel (novel agents), received other postdocetaxel treatments
(including rechallenge of docetaxel), and did not receive any
postdocetaxel treatment (35.3 months vs. 20.8 months vs. 15.3
months, P ¼ 0.00057; novel agents vs. other postdocetaxel treat-
ment, P ¼ 0.00314; Fig. 2).Fig. 2. Overall survival stratiﬁed by postdocetaxel treatment.
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This study illustrated the importance of postdocetaxel treat-
ment and duration of docetaxel-based chemotherapy (8 cycles)
in mCRPC patients, based on the statistically signiﬁcant positive
correlation with OS in the multivariate analysis. Additionally,
patients who had received postdocetaxel novel agents including
abiraterone and cabazitaxel had signiﬁcantly longer OS
compared with those who did not receive any postdocetaxel
treatment and those who received other postdocetaxel treat-
ments including rechallenge of docetaxel. The superiority of
postdocetaxel novel agents over other postdocetaxel treatments
including rechallenge of docetaxel in terms of survival beneﬁt is
supported by the robust evidence for the former in contrast to
the lack of supporting evidence for the latter.5,6 In this privileged
era of plentiful novel agents available in the market, the
optimal sequence of systemic treatment in mCRPC remains to be
deﬁned, and the importance of docetaxel in mCRPC is being
challenged by the promising results of the COU-AA-302 study.9
Although the results of studies addressing the optimal
sequence and agents in managing mCRPC are still being eagerly
awaited, this study has consolidated the approach of maximizing
exposure to docetaxel-based chemotherapy followed by novel
agents, a sensible strategy with exceptional additive survival
results.
The intricate interaction between taxane and androgen
signaling pathway has been the subject of extensive research
previously.11e15 Taxanes are shown to interact with androgen
signaling in prostate cancer cells at both the cytoplasmic level (via
microtubules) and the nuclear level, affecting the transcriptional
regulators of androgen-responsive gene expression.12,16e18 Data
from clinical trials suggest that prior new generation hormonal
therapies, particularly abiraterone or enzalutamide, can poten-
tially decrease the subsequent efﬁcacy of taxanes in treating
prostate cancer. Mezynski et al.19 demonstrated that the activity of
docetaxel post-abiraterone setting is unexpectedly lower than
anticipated, with only 26% of participants showing a 50% PSA
decline rate, in contrast to rates of 45% in the TAX327 study.
Meanwhile, Schweizer et al.20 illustrated that mCRPC patients
receiving abiraterone prior to docetaxel were more likely to
progress on docetaxel and less likely to achieve a PSA response
than abiraterone-naïve patients. The underlying hypothesis is that
abiraterone, an androgen synthesis inhibitor, may modify the tu-
mor biology into a more androgen-insensitive condition. This
would lead to the development of acquired cross-resistance to the
subsequent taxane, which exerts its antitumorogenic effect via
inhibition of the androgen signaling pathway, in patients with
prior abiraterone. This hypothesis is supported by van Soest
et al.'s21 preclinical study, in which the impaired efﬁcacy of
docetaxel and cabazitaxel in the abiraterone-resistant cell line
was found. Conversely, results from clinical trials, COU-AA-301
and AFFIRM, have highlighted the persistent responsiveness to
androgen-targeted therapy with prior chemotherapy, which
might imply that these novel androgen-targeted therapies should
suitably be reserved after taxane treatments.5,7 In our study,
postdocetaxel novel agents were found to be signiﬁcantly asso-
ciated with enhanced OS, and this ﬁnding is in line with the
substantial improvement in survival with novel agents after
chemotherapy in the aforementioned studies. The potential ad-
ditive survival beneﬁt with the sequence of taxane followed by
novel agents, as illustrated in our study, may not be achieved if the
sequence is reversed.
In our study, the duration of chemotherapy (8 cycles) had a
signiﬁcant impact on OS. In the pivotal studies establishing the
survival advantage of docetaxel-based chemotherapy, patientsreceived up to 10 cycles of treatment if no progression or no
prohibitive toxicities were noted.1 To date, however, the optimal
number of cycles of docetaxel chemotherapy remains unclear.
Retrospective studies had compared the survival results among
patients receiving 10 cycles and <10 cycles of chemotherapy.3,4
The results are conﬂicting, but owing to their retrospective fea-
tures, conﬁrmatory data in regard to the optimal number of cy-
cles of chemotherapy are lacking. Our ﬁndings of signiﬁcant
favorable impact on OS with eight or more cycles of chemo-
therapy may just be a reﬂection of the patient's tolerability and
biochemical response. Nonetheless, unless untoward treatment-
related complications and discouraging response are encoun-
tered, our results suggest that patients having eight or more
cycles of chemotherapy may lead to a more favorable clinical
outcome.
Meanwhile, this study has also afﬁrmed the tolerability and
efﬁcacy of docetaxel-based chemotherapy in Chinese mCRPC pa-
tients. In our study, the median cycle of chemotherapy is compar-
atively smaller than that of TAX 327 (6 in the current study vs. 9 in
TAX 327), and a certain proportion of patients require a modiﬁed
starting dose of docetaxel. These ﬁndings can be attributed to the
signiﬁcant differences between Asian and Caucasian patients
regarding the intrinsic pharmacokinetics and pharmacodynamics,
which could inﬂuence the tolerability of docetaxel-based chemo-
therapy.22 The incidence of febrile neutropenia in this cohort is
slightly higher than in previous reports (14% in the current study vs.
3e5% in TAX 327 and SWOG 9916 studies). This is in concordance
with the ﬁndings that Asians are susceptible to chemotherapy-
induced myelosuppresion.23,24 Preemptive primary G-CSF should
be considered in Chinese mCRPC patients when docetaxel-based
chemotherapy is initiated.
The efﬁcacy of docetaxel-based chemotherapy in this study is
comparable to that in TAX 327 and SWOG 9916 studies. The PSA
response (50% PSA decline from the baseline) in this study is
57.9%, which is similar to the rates found in the cited studies (45%
in TAX 327, 50% in SWOG 9916). The magnitude of pain alleviation
after chemotherapy is unexpectedly better than in a previous
report (64.7% in the current study vs. 35% in TAX 327), and this
could be explained by the fact that half of the patients with
improvement in pain control had received palliative radiotherapy
or bisphosphonates within 3 months of docetaxel-based chemo-
therapy. The median OS in the current study (20.8 months) is
comparable to that of TAX 327 (18.9 months) and SWOG 9916
studies (17.5 months). Because our study had included patients
who received novel agents such as abiraterone and cabazitaxel,
which were not available when TAX 327 and SWOG 9916 studies
were ongoing, the duration of the median OS in our study might
numerically lengthen them.
Our study has several limitations. First, despite the fact that
novel agents are demonstrated to have a signiﬁcant impact on
survival in our study, they only became accessible since 2010, and
longer follow-up is mandatory in order to validate their robust-
ness. Second, the number of patients included in this study is not
large enough, and the results may be subject to patient selection
bias. Third, we understand that the longer cycle of chemotherapy
that led to better survival in this study may simply be a reﬂection
of the good response (lead-time bias) and is subject to selection
bias. Finally, the survival results may not be mature enough, and
further follow-up is required to validate the study results. In
conclusion, our study has illustrated that docetaxel-based
chemotherapy is tolerable and efﬁcacious in Chinese mCRPC pa-
tients. Meanwhile, our ﬁndings suggest that maximizing expo-
sure to docetaxel-based chemotherapy followed by novel
therapies would have a favorable survival impact on mCRPC
patients.
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